Search results for "Replacement"

showing 10 items of 561 documents

Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy.

2009

Background Hereditary angioedema caused by mutations in the factor XII gene is a recently described disease entity that occurs mainly in women. It differs from hereditary angioedema caused by C1 inhibitor deficiency. Objective To assess the clinical symptoms, factors triggering acute attacks, and treatments of this disease. Methods Thirty-five female patients with hereditary angioedema and the factor XII mutations p.Thr309Lys and p.Thr309Arg who came from 13 unrelated families were studied. The observation period was 8.4 years on average (range, 2-26 years). Results Patients had on average 12.7 ± 7.9 angioedema attacks per year. Recurrent facial swellings occurred in all patients; skin swel…

Adultmedicine.medical_specialtyAbdominal painAdolescentmedicine.medical_treatmentImmunologyMutation MissenseSeverity of Illness IndexC1-inhibitorYoung AdultRisk FactorsSurveys and QuestionnairesImmunology and AllergyMedicineHumansHereditary Angioedema Type IIIAge of OnsetChildProgesteroneDanazolPregnancyAngioedemabiologybusiness.industryDanazolAngioedemas HereditaryHormone replacement therapy (menopause)Middle Agedmedicine.diseaseDermatologySurgeryPedigreeTranexamic AcidHereditary angioedemaFactor XIIbiology.proteinFemalemedicine.symptombusinessmedicine.drugThe Journal of allergy and clinical immunology
researchProduct

Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial

2015

Objective: To report and discuss the multi-domain impact of elosulfase alfa, with focus on tertiary and composite endpoints, in the 24-week, randomized, double-blind, placebo-controlled phase 3 trial in patients with Morquio A syndrome (mucopolysaccharidosis IVA). Methods: Patients with Morquio A syndrome >= 5 aged years were randomized 1:1:1 to elosulfase alfa 2.0 mg/kg/week (qw; N = 58), elosulfase alfa 2.0 mg/kg/every other week (qow; N = 59), or placebo (N = 59) for 24 weeks. Primary and secondary efficacy measures were 6-minute walk test (6MWT; primary), 3-minute stair climb test (3-MSCT) and urinary keratan sulfate (KS). Safety was also evaluated. Tertiary efficacy measures included r…

Adultmedicine.medical_specialtyAdolescentIdursulfaseMucopolysaccharidosisEndocrinology Diabetes and MetabolismPlaceboBiochemistrylaw.inventionYoung Adultchemistry.chemical_compoundEndocrinologyDouble-Blind MethodRandomized controlled trialElosulfase alfalawSurveys and QuestionnairesInternal medicineActivities of Daily LivingmedicineGeneticsHumansEnzyme Replacement TherapyRespiratory functionYoung adultChildMolecular Biologybusiness.industryMucopolysaccharidosis IVMaximal Voluntary VentilationMiddle Agedmedicine.diseaseBody HeightChondroitinsulfatasesRespiratory Function TestsTreatment OutcomechemistryChild PreschoolPhysical therapyPopulation studybusinessmedicine.drugMolecular genetics and metabolism
researchProduct

Effect of oestrogen/gestagen replacement therapy on liver enzymes in patients with Ullrich-Turner syndrome.

1995

The absence of breast development and the prevention of osteoporosis in Ullrich-Turner syndrome (UTS) require oestrogen/gestagen substitution therapy. In 8 out of 35 (23%) patients with UTS treated with conjugated equine oestrogens and cyclically with norethisterone acetate, the serum liver enzymes increased to conspicuous levels (AST 35; 20-73 U/l, ALT 92; 37-141 U/l, GGT 77; 25-227 U/l, [median; min-max]). These findings were compared with those in 41 tall girls who received a six-fold larger dose of conjugated equine oestrogens for the reduction of final height. None of these 41 girls showed abnormal serum liver enzyme levels. The conspicuous rise in serum liver enzyme levels occurred in…

Adultmedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentOsteoporosisTurner SyndromeLiver Function TestsInternal medicineTurner syndromeBiopsymedicineHumansAspartate AminotransferasesSexual MaturationChildChemotherapyEstrogens Conjugated (USP)medicine.diagnostic_testbusiness.industryEstrogen Replacement TherapyAlanine Transaminasegamma-Glutamyltransferasemedicine.diseaseNorethisterone acetateBody HeightNorethindrone AcetateEndocrinologyEstrogenPediatrics Perinatology and Child HealthToxicityFemaleNorethindroneLiver function testsbusinessmedicine.drugFollow-Up StudiesEuropean journal of pediatrics
researchProduct

The internal calcar septum and its contact with the virtual stem in THR: a computer tomographic evaluation.

2003

The internal calcar septum is a ridge of cortical bone protruding from the inner cortical wall of the proximal femur into the medullary canal. It extends from the lesser trochanter into the femoral neck and narrows the femoral cavity in its dorsal third. This region is essential for THR stability, but the degree of contact between the septum and standard THR implants has never been studied. We obtained CT scans of 50 arthrotic hip joints from patients requiring THR. Virtual stems (50 straight/wedge-shaped and 50 anatomic stems) were placed in CT images of the femora using a PC-based preoperative planning unit. The dimensions of the septum, degree and location of contact between the septum a…

Adultmedicine.medical_specialtyCalcarMedullary cavitybusiness.industryArthroplasty Replacement HipAnatomyRoboticsMiddle Agedmedicine.anatomical_structureLesser TrochanterOrthopedic surgerymedicineImage Processing Computer-AssistedHumansOrthopedics and Sports MedicineSurgeryCortical boneFemurImplantFemurHip ProsthesisbusinessTomography X-Ray ComputedFemoral neckActa orthopaedica Scandinavica
researchProduct

Lipoprotein(a) and aortic valve stenosis: A casual or causal association?

2022

Abstract Aims This review aims to provide an update of available methods for imaging calcification activity and potential therapeutic options. Data Synthesis: Aortic valve calcification represents the most common heart valve condition requiring treatment among adults in Western societies. No medical therapies are proven to be effective in treating symptoms or reducing disease progression. Therefore, surgical or transcatheter aortic valve replacement remains the only available treatment option. Elevated circulating concentrations of lipoprotein(a) is strongly associated with degenerative aortic stenosis. This relationship was first observed in prospective observational studies, and the causa…

Adultmedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentMedicine (miscellaneous)Settore MED/11 - Malattie dell'Apparato CardiovascolareAortic valve stenosisAortic valve calcification; Aortic valve stenosis; Drug therapy; Lipoprotein (a)Valve replacementLipoprotein (a)Internal medicinemedicineHumansProspective StudiesHeart valveNutrition and Dieteticsbiologybusiness.industryCalcinosisLipoprotein(a)medicine.diseaseObservational Studies as TopicStenosismedicine.anatomical_structureAortic ValveAortic valve stenosisAortic valve calcificationbiology.proteinCardiologyObservational studyDrug therapyAortic valve calcificationCardiology and Cardiovascular MedicinebusinessLipoprotein(a)CalcificationNutrition, Metabolism and Cardiovascular Diseases
researchProduct

Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.

2003

Summary: Fabry disease is an X-linked glycosphingolipid storage disorder caused by a deficiency of α-galactosidase A. Affected patients experience debilitating neuropathic pain and have premature mortality due to renal failure, cardiovascular disease or cerebrovascular complications. The disease may be X-linked dominant, since most females heterozygous for Fabry disease are affected clinically. We evaluated the safety, efficacy and pharmacokinetics of agalsidase alfa (Replagal) administered intravenously to female patients with Fabry disease in an open-label, single-centre study. Fifteen severely affected patients received agalsidase alfa at 0.2 mg/kg every other week for up to 55 weeks. Ag…

Adultmedicine.medical_specialtyHeterozygoteAdolescentArthritisRenal functionKidneyGastroenterologyAntibodiesArthritis RheumatoidElectrocardiographyPharmacokineticsInternal medicineGeneticsmedicineHumansGenetics (clinical)Vascular diseasebusiness.industryTrihexosylceramidesEnzyme replacement therapymedicine.diseaseFabry diseaseRecombinant ProteinsSurgeryClinical trialIsoenzymesEchocardiographyalpha-GalactosidaseNeuropathic painMutationFabry DiseaseFemalebusinessJournal of inherited metabolic disease
researchProduct

Hypogonadism and Hormone Replacement Therapy on Bone Mass of Adult Women with Thalassemia Major

2002

We studied bone mass and metabolism in 30 adult women (age 28.5 +/- 1.3) with thalassemia major (TM) and evaluated whether prolonged hormone replacement therapy (HRT) was able to optimize bone accrual. TM patients had reduced bone mass, increased bone turnover and lower serum gonadotropin and estradiol levels compared with 10 normal women of similar age. A significant correlation was found between bone mass and sex hormone levels. Six TM patients with normal ovarian function had normal bone turnover markers and modestly low bone mass (lumbar spine -1.29 +/- 0.31; femoral neck -0.60+/-0.21; Z-score). The other 24 TM women were hypogonadic and had significantly lower bone mass for age (lumbar…

Adultmedicine.medical_specialtyHormone Replacement TherapyEndocrinology Diabetes and MetabolismThalassemiaOsteoporosisBone remodelingAdult womenEndocrinologySex hormone-binding globulinBone DensityInternal medicinemedicineHumansOrthopedics and Sports MedicineFemoral neckEstradiolbiologybusiness.industryHypogonadismbeta-ThalassemiaOsteoporosiLuteinizing Hormonemedicine.diseaseThalassaemiaEndocrinologymedicine.anatomical_structureTransgender hormone therapyOrthopedic surgerybiology.proteinFemaleFollicle Stimulating HormonebusinessCalcified Tissue International
researchProduct

Analysis of serum and endometrial progesterone in determining endometrial receptivity.

2021

Abstract STUDY QUESTION Is there a relationship between serum and endometrial progesterone (P4) levels, including P4 and metabolites (oestrone, oestradiol and 17α-hydroxyprogesterone), and endometrial receptivity? SUMMARY ANSWER Serum P4 levels were not correlated with endometrial P4, nor associated with endometrial receptivity as determined by the ERA® test; however, endometrial P4 and 17α-hydroxyprogesterone levels were positively correlated and related to endometrial receptivity by ERA. WHAT IS KNOWN ALREADY Acquisition of endometrial receptivity is governed by P4, which induces secretory transformation. A close relationship between serum P4 and pregnancy outcome is reported for hormone …

Adultmedicine.medical_specialtyPregnancy Ratemedicine.medical_treatmentPopulationUterusLuteal phaseEndometriumEndometriumPregnancyMedicine17a-hydroxyprogesterone ERA test P4 endometrial receptivity progesterone steroid hormones metabolitesHumansEmbryo ImplantationProspective StudieseducationProspective cohort studyProgesteroneGynecologyeducation.field_of_studyPregnancymedicine.diagnostic_testbusiness.industryRehabilitationObstetrics and GynecologyHormone replacement therapy (menopause)medicine.diseaseEmbryo Transfermedicine.anatomical_structureReproductive MedicineFemalebusinesshormones hormone substitutes and hormone antagonistsEndometrial biopsyHuman reproduction (Oxford, England)
researchProduct

Characteristics of urinary luteinizing hormone (LH) during the induction of LH surges of different magnitude in blood

1995

Urinary luteinizing hormone (LH) testing has been proposed as a reliable method for the prediction of ovulation but its accuracy has been challenged by some studies. To check how accurately the oscillations of urinary LH reflected the plasma changes, surges of LH of different magnitude and duration were artificially induced in plasma and the hormone was measured simultaneously in urine. Post-menopausal women (n = 16) were stimulated during 1 week with a combination of transdermal oestradiol (400 micrograms) and i.m. progesterone (25 mg on day 4, 50 mg on day 5) to obtain an LH discharge comparable with the pre-ovulatory LH peak. A short and moderate peak of LH was induced by the i.v. inject…

Adultmedicine.medical_specialtyTime Factorsmedicine.drug_classmedia_common.quotation_subjectRadioimmunoassayGonadotropin-releasing hormoneUrineBuserelinSensitivity and SpecificityGonadotropin-Releasing HormoneAndrologyInternal medicinemedicineHumansOvulationProgesteronemedia_commonOvulation DetectionEstradiolChemistryEstrogen Replacement TherapyRehabilitationReproducibility of ResultsObstetrics and GynecologyLuteinizing HormoneMiddle Agedmedicine.diseaseBuserelinMenopauseEndocrinologyReproductive MedicineFemaleMenopauseGonadotropinLuteinizing hormonemedicine.drugHormoneHuman Reproduction
researchProduct

A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease

2009

Although Fabry disease is X linked and considered to affect primarily male hemizygotes, female heterozygotes may experience all the signs and symptoms of this metabolic disorder. This prospective, single-center, open-label, clinical trial was performed to evaluate the long-term response of female patients with Fabry disease to enzyme replacement therapy.Symptomatic women (average age = 47 years) enrolled in this 4-year study were treated with agalsidase alfa (Replagal, Shire HGT, Inc.) at a dose of 0.2 mg/kg, every other week for 4 years (N = 36). Clinical and biochemical assessments were conducted at 12-month intervals.The Mainz Severity Score Index, a measure of total disease burden, was …

Adultmedicine.medical_specialtyTreatment outcomeSeverity of Illness IndexDrug Administration ScheduleYoung Adultstomatognathic systemInternal medicineSeverity of illnessLeukocytesmedicineHumansProspective StudiesProspective cohort studyGenetics (clinical)AgedAnalysis of Variancebusiness.industryvirus diseasesEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry diseaseRecombinant Proteinsdigestive system diseasesIsoenzymesClinical trialTreatment OutcomeTolerabilityalpha-GalactosidaseMutationPhysical therapyFabry DiseaseFemalebusinessAgalsidase alfaGlomerular Filtration RateGenetics in Medicine
researchProduct